Abstract
We conducted experimental and clinical studies on cefotetan (CTT, YM09330).
Among the 26 strains of clinically isolated bacteria, cefotetan effectively inhibited 3 out of 5 strains of E. coli at≤0.2μg/ml and 2 strains of K. pneumoniae and 3 strains of P. mirabilis at 0.1μg/ml. It also proved to be several levels superior to other drugs against P. vulgalis.
Clinical results based on a total of 19 cases (11 cases of respiratory tract infections and 8 cases of urinary tract infections) showed that when this drug was administered by drip-infusion twice a day, each time 0.5 to 2g over a period of 4 to 14 days, the effective rate for all cases was 66.7% being 70% for respiratory tract infections and 62.5% for urinary tract infections. No side-effects were observed except for one case in which a transitory elevation in S-GOT and S-GPT was seen.
